Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates
Globe Newswire•05/11/2026•16:07 ET
0
Key Highlights
- ➤Q3 revenue $32.9 million, up 1% year over year
- ➤Nine-month revenue $86.5 million, down $6.5 million year over year
- ➤Full-year 2026 revenue guidance of $100.5-$111.0 million affirmed
- ➤Nine-month net loss $35.3 million, versus $4.6 million net income
- ➤F351 NMPA decision anticipated by year-end 2026 or Q1 2027
Expert Statements
Ying Luo, President and Chief Executive Officer of Gyre Therapeutics
“I am pleased with our execution in the third quarter, our first full quarter incorporating Cullgen's operations within Gyre Therapeutics. We are advancing our protein degrader pipeline toward first-in-human data and initiating new clinical programs next year. Meanwhile, after recently completing an onsite inspection by China’s National Medical Products Administration, or NMPA, we continue to prepare for the China NMPA decision on F351 for CHB-induced liver fibrosis, which we anticipate launching, if approved, sometime in the first half of 2027. Together, these programs are expected to drive our next phase of growth and demonstrate the strength of our unique business model, combining U.S. innovation with capital-efficient operations in China.”
Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed
SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), a U.S. biopharmaceutical company with research operations and commercial business in China to advance global development of protein degrader therapeutics, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.
Get started
Create a free account to read the full story.